230 related articles for article (PubMed ID: 22745572)
1. Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System.
Tamura T; Sakaeda T; Kadoyama K; Okuno Y
Int J Med Sci; 2012; 9(5):322-6. PubMed ID: 22745572
[TBL] [Abstract][Full Text] [Related]
2. Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.
Tamura T; Sakaeda T; Kadoyama K; Okuno Y
Int J Med Sci; 2012; 9(6):441-6. PubMed ID: 22859904
[TBL] [Abstract][Full Text] [Related]
3. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Kadoyama K; Miki I; Tamura T; Brown JB; Sakaeda T; Okuno Y
Int J Med Sci; 2012; 9(1):33-9. PubMed ID: 22211087
[TBL] [Abstract][Full Text] [Related]
4. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
Kadoyama K; Kuwahara A; Yamamori M; Brown JB; Sakaeda T; Okuno Y
J Exp Clin Cancer Res; 2011 Oct; 30(1):93. PubMed ID: 21970649
[TBL] [Abstract][Full Text] [Related]
5. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations.
Sakaeda T; Kadoyama K; Okuno Y
Int J Med Sci; 2011; 8(6):487-91. PubMed ID: 21897761
[TBL] [Abstract][Full Text] [Related]
6. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
Sakaeda T; Kadoyama K; Okuno Y
PLoS One; 2011; 6(12):e28124. PubMed ID: 22205938
[TBL] [Abstract][Full Text] [Related]
7. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system.
Kadoyama K; Sakaeda T; Tamon A; Okuno Y
Biol Pharm Bull; 2012; 35(6):967-70. PubMed ID: 22687540
[TBL] [Abstract][Full Text] [Related]
8. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Clark DW; Strandell J
Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
[TBL] [Abstract][Full Text] [Related]
9. Severe hypomagnesemia and hypoparathyroidism induced by omeprazole.
Rodríguez Ortega P; Rebollo Pérez I; Laínez López M; Roldán Mayorga E; Hernández Lavado R; Creagh Cerquera R
Endocrinol Nutr; 2013 Mar; 60(3):156-7. PubMed ID: 22627012
[No Abstract] [Full Text] [Related]
10. Recent safety concerns with proton pump inhibitors.
Chen J; Yuan YC; Leontiadis GI; Howden CW
J Clin Gastroenterol; 2012 Feb; 46(2):93-114. PubMed ID: 22227731
[TBL] [Abstract][Full Text] [Related]
11. A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database.
Sun Y; Zhang A; Zuo M; Chen J; Zhu L
J Gastroenterol Hepatol; 2024 Feb; 39(2):289-296. PubMed ID: 37961012
[TBL] [Abstract][Full Text] [Related]
12. Data mining of the public version of the FDA Adverse Event Reporting System.
Sakaeda T; Tamon A; Kadoyama K; Okuno Y
Int J Med Sci; 2013; 10(7):796-803. PubMed ID: 23794943
[TBL] [Abstract][Full Text] [Related]
13. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.
Sakaeda T; Kadoyama K; Yabuuchi H; Niijima S; Seki K; Shiraishi Y; Okuno Y
Int J Med Sci; 2011; 8(4):332-8. PubMed ID: 21611115
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.
Davies M; Wilton LV; Shakir SA
Drug Saf; 2008; 31(4):313-23. PubMed ID: 18366242
[TBL] [Abstract][Full Text] [Related]
15. Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases.
Neishi M; Hamano H; Niimura T; Denda M; Yagi K; Miyata K; Lin TJ; Higashionna T; Goda M; Zamami Y; Ishizawa K; Nawa H
Toxicol Appl Pharmacol; 2023 Sep; 475():116632. PubMed ID: 37482254
[TBL] [Abstract][Full Text] [Related]
16. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.
Sakaeda T; Kadoyama K; Minami K; Okuno Y
Int J Med Sci; 2014; 11(5):461-5. PubMed ID: 24688309
[TBL] [Abstract][Full Text] [Related]
17. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Chen G; Ning LJ; Qin Y; Zhao B; Mei D; Li XM
J Gastroenterol Hepatol; 2021 Jan; 36(1):156-162. PubMed ID: 32542684
[TBL] [Abstract][Full Text] [Related]
18. In brief: PPI's and hypomagnesemia.
Med Lett Drugs Ther; 2011 Apr; 53(1361):25. PubMed ID: 21464802
[No Abstract] [Full Text] [Related]
19. Esomeprazole: a clinical review.
Johnson TJ; Hedge DD
Am J Health Syst Pharm; 2002 Jul; 59(14):1333-9. PubMed ID: 12132559
[TBL] [Abstract][Full Text] [Related]
20. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors.
Bezabeh S; Mackey AC; Kluetz P; Jappar D; Korvick J
Oncologist; 2012; 17(4):550-4. PubMed ID: 22477728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
